Intraoperative Dexamethasone Intravitreal Implant (Ozurdex) in Vitrectomy Surgery for Epiretinal Membrane.

Autor: Hostovsky A; Department of Ophthalmology & Vision Sciences, The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada., Muni RH; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada.; Department of Ophthalmology, St.Michael's Hospital, Toronto, Canada., Eng KT; Department of Ophthalmology & Vision Sciences, The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada., Mulhall D; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada., Leung C; Department of Ophthalmology & Vision Sciences, The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada., Kertes PJ; Department of Ophthalmology & Vision Sciences, The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada.
Jazyk: angličtina
Zdroj: Current eye research [Curr Eye Res] 2020 Jun; Vol. 45 (6), pp. 737-741. Date of Electronic Publication: 2019 Dec 10.
DOI: 10.1080/02713683.2019.1697454
Abstrakt: Objective : To study the effectiveness and safety of the intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in vitrectomy surgery for epiretinal membrane. Methods : This is a prospective, multicenter, pilot study. Inclusion criteria included visually significant (<20/50) idiopathic epiretinal membrane. All patients underwent 23-gauge pars plana vitrectomy with membrane peeling and Ozurdex implant injection. The primary outcome measure was best corrected visual acuity (BCVA) change at 3 months. Secondary outcomes included BCVA at 6 months and changes in central retinal thickness (CRT). Intraocular (IOP) changes were monitored and cataract progression in phakic patients was documented. Results : 15 patients were enrolled in the study, 12 eyes of 12 patients were included in the analysis. Mean preoperative BCVA was 50.67 ETDRS letters and improved significantly to 63.67 (+12.91 letters, p = .008) at 3 months. Mean CRT improved from 548 to 409 microns ( p = .002) at 3 months. The IOP showed mild elevation at months 1 and 2 and returned almost to baseline at month six. There were no complications related to the steroid implant injection procedure in an air-filled eye. Conclusions : Intra-operative injection of Ozurdex® at the conclusion of PPV can be done safely. The peak IOP and lowest CRT after 2 months strengthens the findings of prior studies demonstrating Ozurdex activity up to 3 months in vitrectomized eyes.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje